# Wall Street Analysts Raise Mirum Pharmaceuticals Price Target to $151.64

- URL: https://stocks.freetheai.org/news/wall-street-analysts-raise-mirum-pharmaceuticals-price-target-to-151-64-22342b
- Published: 2026-10-12T22:20:06Z
- Category: analyst_ratings; sentiment: bullish; impact: medium
- Symbols: [NASDAQ:MIRM](https://stocks.freetheai.org/symbols/NASDAQ-MIRM)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Wall Street analysts covering Mirum Pharmaceuticals, Inc. (MIRM) have increased their average 12-month price target for the company to $151.64 per share, up from a previous average of $148.86. The updated figure reflects forecasts from 14 analysts, whose individual price targets span from $118 to $200.

The revised target suggests roughly 76% potential upside relative to the stock's closing price of $86.06 on October 9. Sentiment among covering analysts remains overwhelmingly positive, with all 14 maintaining a Buy rating on the stock and none recommending a Hold or Sell.

Investors will be watching whether upcoming corporate announcements and financial results help propel the stock toward Wall Street's higher forecasts. With price targets topping out at $200 per share, market participants will track how future operational developments influence analyst expectations.

## Key points

- Analysts raised their average 12-month price target for Mirum Pharmaceuticals, Inc. from $148.86 to $151.64.
- The updated price target represents approximately 76% potential upside relative to the October 9 closing price.
- Individual price targets among 14 covering analysts range between $118 and $200 per share.
- All 14 analysts covering the company maintain a Buy rating on the stock.

## Questions and answers

### What is the new average price target for Mirum Pharmaceuticals stock?

Wall Street analysts raised the average 12-month price target for Mirum Pharmaceuticals, Inc. to $151.64 per share, up from $148.86.

### How much potential upside does the updated price target imply for MIRM?

Based on the closing price of $86.06 on October 9, the updated average target implies approximately 76% upside. Individual analyst forecasts range from $118 to $200 per share.

### What is the overall analyst consensus rating for Mirum Pharmaceuticals?

The analyst consensus rating remains a unanimous Buy, with all 14 covering analysts rating the stock a Buy and none issuing Hold or Sell ratings.